Acro Biomedical Co., Ltd.
ACBM
$0.105
$0.000.00%
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -39.80% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -39.80% | -- | -- |
| Cost of Revenue | -- | -- | -33.93% | -- | -- |
| Gross Profit | -- | -- | -57.33% | -- | -- |
| SG&A Expenses | -10.84% | -0.10% | -0.32% | 71.91% | 537.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.06% | -5.29% | -3.52% | 34.11% | 209.01% |
| Operating Income | 20.06% | -1.91% | -2.11% | -34.11% | -403.77% |
| Income Before Tax | 20.04% | -1.92% | -2.13% | -34.12% | -402.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.04% | -1.92% | -2.13% | -34.12% | -402.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.04% | -1.92% | -2.13% | -34.12% | -402.91% |
| EBIT | 20.06% | -1.91% | -2.11% | -34.11% | -403.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 20.12% | -1.99% | -2.18% | -27.00% | -324.20% |
| Normalized Basic EPS | 19.95% | -1.96% | -2.24% | -27.05% | -324.49% |
| EPS Diluted | 20.12% | -1.99% | -2.18% | -27.00% | -233.00% |
| Normalized Diluted EPS | 24.76% | -1.96% | -2.24% | -33.97% | -324.49% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | -0.11% | 5.58% | 18.86% |
| Average Diluted Shares Outstanding | 6.44% | 0.00% | -0.11% | 0.38% | 18.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
